A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response (clinicaltrials.gov) - Oct 21, 2026 - P1 | N=88 | Recruiting | Sponsor: Adaxion Therapeutics | Not yet recruiting ➔ Recruiting
Enrollment open
|